Atorvia Health Technologies Information

Atorvia is a pre-clinical stage biopharmaceutical company pioneering novel therapeutic approaches for organ failure, starting in the kidney. Targeting a previously unknown functional role of a protein involved in the regulated cell death pathway, Atorvia’s lead program is a small peptide therapeutic that prevents and treats kidney failure caused by ischemia. An Ontario-based company, Atorvia is advancing a pipeline of technologies that will disrupt the existing organ failure landscape and transform outcomes for patients.